| June 2 |
Acorda Therapeutics Announces Positive Data from Second Phase 3
Study of Fampridine-SR on Walking Ability in People with Multiple
Sclerosis |
| June 2 |
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX
GM-CSF in Metastatic Melanoma at the 2008 American Society of
Clinical Oncology Meeting |
| June 2 |
Apthera's NeuVax Produces Delays in Recurrence in High-Risk
HER2-Positive Prostate Cancer Patients |
| June 2 |
Antisoma plc (UK) - Positive data on Antisoma's ASA404 presented at
ASCO |
| June 2 |
CuraGen Announces Data From Ongoing Phase I/II Trial Showing
Clinical Activity of CR011-vcMMAE in Metastatic Melanoma |
| June 2 |
Clavis Pharma ASA (NO) - Elacyt Clinical Results Presented at ASCO |
| June 2 |
Data from Satraplatin SPARC Phase 3 Trial in Patients with
Hormone-Refractory Prostate Cancer Progressing after Initial
Chemotherapy Presented at 44th ASCO Annual Meeting |
| June 2 |
Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm
c-Met Inhibition in Tumors with ARQ 197, Under Development by
ArQule |
| June 2 |
Data Confirm Avastin Helps Patients With Metastatic Colorectal
Canc... |
| June 2 |
Data To Be Presented at ASCO Supports Potential of Peregrine's
Cotara for the Treatment of Brain Cancer |
| June 2 |
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved
Progression-Free Survival in Women with Advanced HER2-Negative
Breast Cancer |
| June 2 |
YM Biosciences Reports Nimotuzumab Nsclc Clinical Data at ASCO
Annual Meeting |
| June 2 |
Velcade (Bortezomib) for Injection Based Treatment Delivers
Impressive Complete Response and Survival in Patients With Newly
Diagnosed Multiple Myeloma |
| June 2 |
Video: Major Independent Trial Demonstrates Significant Anticancer
Benefit of Zometa in Women With Early-Stage Breast Cancer |
| June 2 |
Vion Pharmaceuticals Announces Presentation of Data from Phase III
Trial of Cloretazine (VNP40101M) and Cytarabine in Relapsed Acute
Myelogenous Leukemia at the ASCO Annual Meeting |
| June 2 |
Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO |
| June 2 |
Updated Data from Ongoing Phase 3 Trials Support the Continued
Study of Vectibix (panitumumab) in Combination with Standard
Chemotherapy |
| June 2 |
Combination Therapy of Solvent-free Abraxane and the Targeted
Therapy Bevacizumab Evaluated as First-line Treatment for
Metastatic Breast Cancer |
| June 2 |
Updated Revlimid Results Presented In Relapsed/Refractory
Aggressive Non-Hodgkin's Lymphoma (NHL) at ASCO |
| June 2 |
Transgene’s Therapeutic Vaccine TG4010 Meets Primary Endpoint
in Non-small Cell Lung Cancer Phase IIb Trial |
| June 2 |
ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with
Targeted Anticancer Compounds IMGN242 and AVE1642 |
| June 2 |
Preliminary Data from Ongoing Phase 1 Data of Investigational
Anti-PD-1 Antibody Presented at American Society of Clinical
Oncology Annual Meeting |
| June 2 |
Novo Nordisk and Neose Announce Completion of Initial Phase 1
Clinical Trial of NN7128 (Long-Acting Factor VIIa) |
| June 2 |
Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO |
| June 2 |
Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of
GVAX Immunotherapy for Prostate Cancer Used in Combination With
Ipilimumab |
| June 2 |
Data from Satraplatin SPARC Phase 3 Trial in Patients with
Hormone-Refractory Prostate Cancer Progressing after Initial
Chemotherapy Presented at 44th ASCO Annual Meeting |
| June 2 |
EntreMed's ENMD-2076 Demonstrates Antitumor Activity in Multiple
Myeloma Model |
| June 2 |
Genta Announces Initial Clinical Trial Results for G4544, a Novel
Potent Drug for Bone Disease |
| June 2 |
Quest PharmaTech Announces Positive Results from Phase I Clinical
Trial of its Photodynamic Therapy for Actinic Keratosis |
| June 2 |
PsychoGenics Announces Positive Phase-IIa for Its First-in-Class
Partial 5-HT1A - 5-HT1B Receptor Agonist in ADHD |
| June 2 |
Sanofi-aventis and Oxford Biomedica Report Encouraging Trovax Phase
II Trial Results in Metastatic Renal Cancer |
| June 2 |
Gloucester Pharmaceuticals Announces Presentation of Romidepsin
Phase 1 Data in Multiple Solid Tumors at ASCO |
| June 2 |
Adherex Announces Updated ADH-1 Chemotherapy Combination Data in
Melanoma |
| June 2 |
Curis Announces GDC-0449 Phase I Clinical Data Presented at
American Society of Clinical Oncology Annual Meeting 2008 |
| June 2 |
New Data Show Patients Using Avonex Reported Less Sick Leave and
Short-Term Disability Costs Than Patients Using Copaxone |
| June 2 |
CytRx to Present Favorable Study Data with Iroxanadine in Diabetic
Wound Healing at the Third Congress of the World Union of Wound
Healing Societies |
| June 2 |
New Positive Data Announced for NKTR-102 (PEG-irinotecan),
Highlights Promise of Nektar's Innovative Small Molecule
PEG-Oncolytics |
| June 2 |
Oculus Innovative Sciences Announces Market Assessment of Near-Term
Commercialization Opportunities in the United States for Dermacyn
Wound Care |
| June 2 |
Jennerex Clinical Trial Data with JX-594 Selected for Plenary
Session Presentation at Major International Conference |
| June 2 |
Isis' Partners Present Clinical Data on Antisense Drugs at the
American Society of Clinical Oncology |
| June 2 |
Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO |
| June 2 |
Combination Therapy of Solvent-Free Abraxane and the Targeted
Therapy Bevacizumab Evaluated as First-Line Treatment for
Metastatic Breast Cancer |
| June 2 |
Abraxane in Combination with Trastuzumab and Carboplatin Evaluated
as First-Line Treatment for Patients with HER2-Positive Metastatic
Breast Cancer |
| June 2 |
VioQuest Pharmaceuticals Presents Phase 1 Data Showing Promising
Immune Response and Safety Profile of Lenocta |
| June 2 |
Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits
in Ongoing Phase I/II Myelofibrosis Study |
| June 2 |
TransMolecular Reports Positive Results from Phase 1 Trial of
(131)Iodine-TM601 in Metastatic Melanoma |
| June 2 |
Molecular Insight Pharmaceuticals, Inc. Reports Preliminary Results
of Azedra Phase I Trial in Neuroendocrine Cancer Patients at ASCO |
| June 2 |
Research Explains How Advanced Prostate Cancer Becomes Resistant to
Androgen-Deprivation Therapy |
| June 2 |
Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and
Tolerability in Systemic Treatment of Pancreatic Carcinoma,
Malignant Melanoma and Colorectal Carcinoma |
| June 2 |
Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in
Phase Iib EMEA provides Guidance on Phase III Design and Approval
Requirements |
| June 2 |
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable
Complete Remissions in Secondary AML |
| June 2 |
Lung Cancer Alliance Hails Announcement of New Erbitux Data |
| June 2 |
Novelos Announces Presentation of Encouraging Results in Phase 2
Ovarian Cancer Trial at 2008 ASCO Meeting by MGH and
Dana-Farber/Harvard Cancer Centers |
| June 2 |
New Nexavar Data Presented in Multiple Tumor Types at 44th American
Society of Clinical Oncology Annual Meeting |
| June 2 |
Schering-Plough's Sugammadex Provides Fast Reversal of Effects of
Muscle Relaxants Used in General Anesthesia |
| June 2 |
IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is
Well Tolerated With Positive Survival Trend in Non-Small Cell Lung
Cancer Patients |
| June 2 |
University of Miami Team Confirms Value of Monitoring Cell-Mediated
Immunity Pre- and Post-Transplant in Management of Kidney
Transplant Recipients |
| June 2 |
Study Suggests Survival Benefit from Radioactive Microsphere
Therapy in Patients with Colorectal Cancer Liver Metastases who
have Failed Chemotherapy |
| June 2 |
Further Clinical Testing of BZL101 in Advanced Breast Cancer
Demonstrates Favorable Efficacy and Toxicity Profiles |
| June 2 |
Stimuvax Phase 1/2 Survival Data Support Prior Results |
| June 2 |
New Publication of Phase 2 Data Shows Maribavir Markedly Reduced
the Rate of Cytomegalovirus Infection and Disease in Bone Marrow
Transplant Patients |
| June 2 |
BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel
DNA Repair Inhibitor |
| June 2 |
Researchers at Signature Characterize Previously Unreported
Microduplication |
| June 2 |
Ipsen and Spirogen's SJG-136 Shows Encouraging Results in the
Treatment of Refractory Solid Tumours At ASCO |
| June 2 |
OncoGenex Reports that Low Serum Clusterin Levels were Predictive
of Survival in Preliminary Analyses of Phase 2 Study of Lead Drug
Candidate OGX-011 |
| June 2 |
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation
Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at
the American Society of Clinical Oncology Meeting in Chicago,
Illinois |
| June 2 |
Geron Presentations at the ASCO 2008 Annual Meeting |
| June 2 |
Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th
Annual ASCO Annual Meeting |
| June 2 |
Vidaza Data Presented at ASCO Demonstrates Significant Overall
Survival for Myelodysplastic Syndrome Patients |
| June 2 |
Metformin Increases Pathologic Complete Response Rates in Breast
Cancer Patients With Diabetes |
| June 2 |
Hana Reports Progress in Phase 2 Uveal Melanoma Trial |
| June 2 |
Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate)
Phase I and Phase II Data at ASCO 2008 Annual Meeting |
| June 2 |
Data Presented at This Year's ASCO Meeting Provide New Insights
into the Treatment of Patients with Myelodysplastic Syndromes |
| June 2 |
Medivation Announces Presentation of Positive MDV3100 Clinical Data
in Castration-Resistant Prostate Cancer Patients at 44th ASCO
Annual Meeting |
| June 2 |
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented
at American Society of Clinical Oncology Annual Meeting |
| June 2 |
US Oncology Affiliated Physicians Make a Strong Showing in ASCO
Proceedings |
| June 2 |
Nimotuzumab Clinical Data Presented at ASCO Annual Meeting |
| June 2 |
Methylgene Reports Clinical Data for MGCD0103 at the 44th American
Society of Clinical Oncology (ASCO) Annual Meeting |
| June 2 |
Early Data Presented at ASCO Show Potential of RAD001 to Enhance
Efficacy of, and Overcome Resistance to, Breast Cancer Treatments |
| June 2 |
Investigational Studies Highlight Potential Utility of Zevalin
(Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell
Transplantation for Non-Hodgkin's Lymphoma |
| June 2 |
Early Data Presented at ASCO Show Potential of RAD001 To Enhance
Efficacy of, and Overcome Resistance to, Breast Cancer Treatments |
| June 2 |
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO
and Provides Clinical Update on Its Phase II Bavituximab Breast
Cancer Study |
| June 2 |
New Data from Several Satraplatin Clinical Trials in Solid Tumors
Presented at 44th ASCO Annual Meeting |
| June 2 |
Oncolytics Biotech Inc. Collaborators Present Positive Phase II
Sarcoma Trial Results at ASCO Annual Meeting |
| June 2 |
IDM Pharma Announces Data Supporting Improved Overall Survival
Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma
Treated with Mifamurtide (L-MTP-PE) |
| June 2 |
Leading Immunologists Convene in Boston |
| June 2 |
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy
and Safety of Clofarabine in Older Adult AML Patients |
| June 2 |
Vion Pharmaceuticals Announces Presentation of Interim Data from
Pivotal Phase II Trial of Cloretazine (VNP40101M) in Acute
Myelogenous Leukemia at the ASCO Annual Meeting |
| June 3 |
Trubion Announces Presentation of Positive TRU-016 Data at ASCO |
| June 3 |
ChemGenex Investigators Present Data on Clinical Activity of
Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients
with the T315I Mutation at ASCO |
| June 3 |
New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung
Cancer and Ewing's Sarcoma |
| June 3 |
Critical Therapeutics Completes Phase II Clinical Trial for
Zileuton Injection |
| June 3 |
Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented
at the 2008 American Society of Clinical Oncology Meeting
Demonstrate Single Agent Anti-Tumor Activity in Western Patient
Population |
| June 3 |
Amylin Pharmaceuticals to Present Promising Data From Diabetes and
Obesity Programs at ADA 2008 |
| June 3 |
Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study
Results of R788 in Lymphoma |
| June 3 |
Analysis Showed No Increased Risk of Hospitalization in Patients
When Adding a LABA to ICS Compared to ICS Alone |
| June 3 |
ThromboGenics and BioInvent Report Positive Phase I Results for
Anti-PlGF Cancer Therapeutic TB-403 |
| June 3 |
Paclitaxel Poliglumex (Opaxio)/Capecitabine Regimen Well Tolerated
and Active in Metastatic Breast Cancer |
| June 3 |
ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the
American Society of Clinical Oncology (ASCO) |
| June 3 |
Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in
Diffuse Large B-Cell and SLL/CLL |
| June 3 |
Auxilium Pharmaceuticals, Inc. Announces Xiaflex Meets Primary
Endpoint With Statistical Significance (p<0.001) in CORD I
Pivotal Phase III Study for Dupuytren's Contracture |
| June 3 |
The Aethlon Hemopurifier Proves Effective in Capturing the
Reconstructed Spanish Flu of 1918 and H5N1 Avian Influenza Virus |
| June 3 |
The GI Company Reports Significant Reduction in Occurrence of Oral
Mucositis in Phase II Study Presented at ASCO |
| June 3 |
EntreMed Presents MKC-1 Phase 2 Data at American Society of
Clinical Oncology Annual Meeting |
| June 3 |
Tolerx Announces Data Presentations at American Diabetes
Association 68th Scientific Sessions 2008 |
| June 3 |
Study of Vidaza in Higher-Risk Myelodysplastic Syndrome Patients
Demonstrates Improved Overall Survival |
| June 3 |
Zysolin Shows Promising Results in Animal Study |
| June 3 |
NexMed Confirms Publication on Anti-Fungal Product |
| June 3 |
Isotechnika To Hold Conference Call to Discuss Positive PROMISE
Trial |
| June 3 |
Transgene’s Therapeutic Vaccine TG4010 Meets Primary Endpoint
Non-small Cell Lung Cancer Phase IIb Trial |
| June 3 |
Virax Co-X-Gene Technology Licence with Transgene Successful Phase
IIb trial Result for TG4010 in Non-Small Cell Lung Cancer |
| June 3 |
Altus Pharmaceuticals Reports ALTU-237 Phase 1 Clinical Trial
Results |
| June 3 |
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of
Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast
Cancer in a Phase 2 Trial |
| June 3 |
Seattle Genetics Reports Multiple Complete and Partial Responses
with SGN-35 in Patients with Lymphoma |
| June 3 |
ImmunoGen, Inc. Announces Presentation of Encouraging Clinical
Findings with Trastuzumab-DM1 at ASCO |
| June 3 |
New Ipilimumab Survival Data in Patients with Metastatic Melanoma
Presented at American Society of Clinical Oncology Annual Meeting |
| June 3 |
ImmunoGen, Inc. Announces Presentation of Encouraging Clinical
Findings with Trastuzumab-DM1 at ASCO |
| June 3 |
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on
KRX-0401 (Perifosine) in Patients with Relapsed/Refractory
Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the
American Society of Clinical Oncology |
| June 3 |
Immtech Announces Results From Hepatitis C Discovery Program |
| June 3 |
Generex Biotechnology Phase I Trial Results for Novel Immunotherapy
Vaccine in Breast Cancer Patients Presented at ASCO |
| June 3 |
On Matters of the Heart, Women Aged 40-plus Naive When It Comes to
Risks |
| June 3 |
New Modified Citrus Pectin Slows Cancer Progression and Stops
Cancer Cells in Their Tracks |
| June 3 |
AVAX Presents Results of a Dose-Response Study of MVax at American
Society of Clinical Oncology (ASCO) |
| June 3 |
Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by
Target Tissues in the Eye |
| June 3 |
Promising Data on Head and Neck Cancer Announced by DNAR at 2008
American Society of Clinical Oncology Meeting |
| June 4 |
Reduced Hepatitis C Viral Level Achieved with DNA Vaccine Delivered
by Inovio Biomedical's Electroporation Delivery System in Phase
I/II Clinical Study |
| June 4 |
NanoViricides Inc. to Present at The NSTI Nanotech 2008 Conference
in Boston |
| June 4 |
Akesis Pharmaceuticals Completes Phase IIa Trial of AKP-020 for
Type 2 Diabetes |
| June 4 |
Celator Pharmaceuticals Announces Positive Phase 2 Results for
CPX-1 in Treatment of Colorectal Cancer |
| June 4 |
Sirtris Pharmaceuticals Presents at the American Diabetes
Association's 68th Annual Scientific Sessions June 8 |
| June 4 |
VIVUS Announces the Podium Presentation of Phase 2 Data for Qnexa
in Type 2 Diabetics at the American Diabetes Association Meeting |
| June 4 |
Isotechnika Presents Positive Data from the Promise Trial of
Voclosporin at the American Transplant Congress |
| June 4 |
Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA
Conference |
| June 4 |
Intravenous Iron May Help Treat Anemia in Patients with Kidney
Disease |
| June 4 |
Somaxon Pharmaceuticals to Present Data at the 22nd Annual Meeting
of the Associated Professional Sleep Societies |
| June 4 |
Semafore Pharmaceuticals Reports Positive Interim Results from a
Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients
with Advanced Solid Tumors |
| June 4 |
Interim Phase 2 Results on Prospect Therapeutics' GCS-100 Presented
at the 10th International Conference on Malignant Lymphoma |
| June 4 |
Transcept Pharmaceuticals Announces Intent to Submit New Drug
Application for Intermezzo in Third Quarter 2008 |
| June 4 |
CellCept and a Reduced Level of CNI Shows Trend Towards
Preservation of Kidney Function Versus a Standard-Dose CNI |
| June 4 |
World's Leading Health Experts Urge Countries to Use Newly Released
Data to Prevent the Death of Millions of Children Due to Rotavirus |
| June 4 |
New Diabetes Research To Be Presented at FOCIS Annual Meeting |
| June 4 |
World's Leading Health Experts Urge Countries to Use Newly Released
Data to Prevent the Death of Millions of Children Due to Rotavirus |
| June 4 |
Racial Disparities in the Outcomes of Patients with Chronic Kidney
Disease Abound |
| June 5 |
Promise of Vical's CMV Vaccine Noted by Independent Experts |
| June 5 |
Inovio Biomedical Provides Updated Interim Data on Phase I/II
Clinical Study of Electroporation-Delivered Prostate Cancer DNA
Vaccine at ASGT Annual Meeting |
| June 5 |
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates
Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma |
| June 5 |
Novel Investigational Regimen Combining Radiation Enhancing Agent
With Ibritumomab Tiuxetan (Zevalin) Produces High Rate of Complete
Responses in Patients With Rituximab-Refractory Follicular
Non-Hodgkin's Lymphoma |
| June 5 |
Regado Biosciences Announces Publication in Circulation of Clinical
Trial Results of REG1 Anticoagulation System |
| June 5 |
Arana Therapeutics Completes Second Project with CSL |
| June 5 |
Positive Clinical Data Evaluating the Micrus Endovascular Cerecyte
Microcoil Published in Peer-Reviewed Journals |
| June 5 |
SemBioSys Demonstrates Functionality of its Safflower Produced Apo
AI(Milano) |
| June 5 |
Ardea to Present Data on Inflammation Programs at 2008 Annual
European Congress of Rheumatology |
| June 5 |
MacroChem Announces Presentation by Michael Zasloff, MD, PhD on
Topical Therapy for Diabetic Foot Infection |
| June 5 |
Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted
Radiation Therapy Demonstrates High Complete Response Rate in
Patients With Non-Hodgkin's Lymphoma |
| June 5 |
Nuvelo Announces Publication of Preclinical Data From Wnt
Therapeutics Program |
| June 5 |
Senesco Expands on Preclinical Multiple Myeloma Findings |
| June 5 |
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma
Data at International Conference on Malignant Lymphoma |
| June 5 |
Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma
Data at International Conference on Malignant Lymphoma |
| June 5 |
New Data Show Potential of Rasilez to Protect Kidneys from Damage
Independent of Its Proven Ability to Lower Blood Pressure |
| June 5 |
Study Supports Possible Use of Leukine as a Potential Adjuvant
Therapy for High-Risk Melanoma Patients |
| June 5 |
Gloucester Pharmaceuticals Announces Podium Presentation of
Positive Results from Phase 2b Registration Trial of Romidepsin in
Refractory CTCL |
| June 5 |
Monotherapy Reveals Significant Biological Activity without
Toxicity in Chemo-Resistant Metastatic Breast Cancer |
| June 6 |
TriMix Gel Achieves Success Among Men Who Have Failed to Achieve
Erections With Viagra, Levitra and Cialis Type Tablets |
| June 6 |
Allos Therapeutics Announces Interim Data from Phase 1 Study of PDX
in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma |
| June 6 |
T3Therapeutics, LLC and Archimedes Pharma Ltd Announce Positive
Clinical Results for Novel Oral Modified Release Liothyronine |
| June 6 |
Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial
with Denufosol for Cystic Fibrosis |
| June 6 |
Genelabs Technologies Announces Presentation of Data on
Non-Nucleoside HCV Polymerase Inhibitor at 3rd International
Workshop on Hepatitis C, Resistance and New Compounds |
| June 6 |
Seattle Genetics Announces SGN-35 Plenary Presentation at
International Conference on Malignant Lymphoma |
| June 6 |
Brain Stem Cells Can Be Awakened, Say Schepens Scientists |
| June 6 |
Synvista Therapeutics Reports Results of Three Phase 2 Clinical
Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease |
| June 6 |
CONTRAST Study: To What Extent Do High-Risk Patients Benefit From
the Renal Tolerance of Iso-Osmolar X-Ray Contrast Media? |
| June 9 |
ImmuneRegen BioSciences Confirms Adult Stem Cell Activity of
Homspera in Human Bone Marrow |
| June 9 |
Repros Therapeutics Inc. Announces That Initial Findings for
Proellex Show No Gross Cancer Tumors in First Completed Animal
Carcinogenicity Study |
| June 9 |
Achillion Announces Additional Positive Top-Line Phase 2 Data for
Elvucitabine |
| June 9 |
Accord Clinical Trial Publishes Results |
| June 9 |
Abbott's Phase III Sub-Group Analysis Shows Investigational
TriLipix in Combination with Crestor Improves Key Lipids in
Patients with Mixed Dyslipidemia and Type 2 Diabetes |
| June 9 |
Onglyza (saxagliptin) Demonstrated Significant Reductions in Key
Measures of Glucose Control in Treatment Naive People with Type 2
Diabetes |
| June 9 |
NanoViricides Inc. Posts Photos Showing Rapid Response of Animals
to Treatment with EKC Eye Drug Candidate |
| June 9 |
Hollis-Eden Pharmaceuticals Reports Additional Positive Data from
Phase I/II Clinical Trial with Triolex Supporting Anti-Inflammatory
Approach to Treating Type 2 Diabetes |
| June 9 |
Nastech Announces Positive Intranasal Insulin Data at American
Diabetes Association Meeting |
| June 9 |
Cerus Announces INTERCEPT Blood System Data Presented at
International Society of Blood Transfusion Conference Support Broad
Utility in Safeguarding the Blood Supply |
| June 9 |
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical
Models of Rheumatoid Arthritis and Lymphoma |
| June 9 |
Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based
Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior
Treatment |
| June 9 |
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin) Regimen
Produces Impressive Survival Rates in High Risk Elderly Patients
With Untreated Aggressive Diffuse Large B-cell Lymphoma |
| June 9 |
Arisaph Pharmaceuticals Announces at the ADA that Its Potent DPP 4
Inhibitor (ARI-2243) Possesses an Additional Mechanism that
Contributes to Improved Glucose Control |
| June 9 |
Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3
Investigational Diabetes Therapy, Showed Improvements in Glycemic
Control, Weight |
| June 9 |
Elixir Pharmaceuticals Announces New Data at the 2008 American
Diabetes Association Annual Meeting |
| June 9 |
Sangamo BioSciences Announces Presentation of Phase 1b ZFP
Therapeutic Data at American Diabetes Association Meeting |
| June 9 |
Data from Phase II Clinical Trial of Galiximab in Combination with
Rituximab in Patients with Previously Untreated Follicular Lymphoma
Presented at International Conference on Malignant Lymphoma |
| June 9 |
Generex Biotechnology Presented Data At American Diabetes
Association Scientific Sessions |
| June 9 |
Genaera Corporation Presents Additional Promising Preclinical Type
2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes
Association |
| June 9 |
Nastech Announces Positive Intranasal Insulin Data at American
Diabetes Association Meeting |
| June 9 |
Halozyme Therapeutics Announces Phase I Clinical Trial Results
Demonstrating that the Combination of Recombinant Human
Hyaluronidase (rHuPH20) With Humulin R and with Humalog Yields
Faster, More Physiologic Insulin Kinetics and Better Predictability |
| June 9 |
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar,
Weight, and Blood Pressure in Patients with Type 2 Diabetes |
| June 9 |
Biopure Responds to JAMA and Meta-Analysis |
| June 9 |
Idera Pharmaceuticals Presents Preclinical Data of Toll-Like
Receptor Antagonists in Models of Lung Inflammation and Psoriasis |
| June 9 |
A New Analysis Released at ADA: Lower Risk of Symptomatic
Hypoglycemia with Januvia (sitagliptin) Compared to Glipizide on a
Background of Metformin in Patients with Type 2 Diabetes |
| June 9 |
Lipid Sciences' Autologous Therapeutic HIV Vaccine Study Published
in "Experimental Biology and Medicine" |
| June 9 |
Kamada Announces Successful Interim Results of Phase II Deposition
Study with Aerosolized AAT |
| June 9 |
Hollis-Eden Pharmaceuticals Reports Additional Positive Data from
Phase I/II Clinical Trial with Triolex Supporting Anti-Inflammatory
Approach to Treating Type 2 Diabetes |
| June 9 |
New Discovery of Key Difference in Bile Acid Metabolism in Patients
with Type 2 Diabetes May Suggest Underlying Disorder |
| June 9 |
CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at
Prestigious Immunology Conference |
| June 9 |
Four Independent Research Groups Present Data Generated by Pressure
Cycling Technology (PCT) at the ASMS Conference on Mass
Spectrometry and Allied Topics in Denver, CO |
| June 10 |
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at
ADA Conference |
| June 10 |
Alexza Announces Preliminary Results From its AZ-002 (Staccato
Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic
Disorder |
| June 10 |
OSI Pharmaceuticals Presents Diabetes/Obesity Preclinical
Compounds, PSN821 and PSN602, at Annual Meeting of the American
Diabetes Association |
| June 10 |
Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide,
into Phase III Clinical Trials |
| June 10 |
Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and
Blood Pressure in Patients with Type 2 |
| June 10 |
Use of Mealtime Symlin Compared to Rapid-Acting Insulin for
Diabetes Therapy Intensification in Patients With Type 2 Diabetes
Using Basal Insulin |
| June 10 |
Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates
Improvements in Insulin Sensitivity and Lowers Cholesterol Levels
in Type 2 Diabetics |
| June 10 |
Schizophrenia: Twice as Common as HIV/AIDS, but Survey Shows
Americans Misinformed |
| June 10 |
After One Year, Type 2 Diabetes Patients Taking Exenatide Once
Weekly Sustained Improvements in Glycemic Control and Weight;
DURATION-1 Presented at ADA 2008 |
| June 10 |
High-dose Immunosuppressant Drug Appears to Reduce Disease Activity
and Disability in Patients with Multiple Sclerosis |
| June 10 |
NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy
Study Results in Neurology |
| June 10 |
Acomplia (rimonabant) Significantly Improved Glucose Control in
Type 2 Diabetes Patients Treated with Insulin |
| June 10 |
Five-Year Safety Study Examines the Effect of LANTUS® on the
Progression of Retinopathy in People with Type 2 Diabetes |
| June 10 |
Metabasis Presents Preclinical Results for MB07803, Its Product
Candidate for Type 2 Diabetes, and Its Glucagon Antagonist Program
at the American Diabetes Association Meeting |
| June 10 |
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar,
Weight, and Blood Pressure in Patients with Type 2 Diabetes |
| June 10 |
Results From One-Year Study Suggest Advair Provides Important
Benefits for African American Patients With Asthma |
| June 10 |
Qnexa Reduces Hemoglobin A1c by 1.2 Percent in 28 Weeks |
| June 10 |
After One Year, Type 2 Diabetes Patients Taking Exenatide Once
Weekly Sustained Improvements in Glycemic Control and Weight;
DURATION-1 Presented at ADA 2008 |
| June 10 |
Ambien CR (zolpidem tartrate extended-release) CIV Tablets Improved
Insomnia and Daily Functioning in Patients with Co-Morbid Major
Depressive Disorder |
| June 10 |
Array BioPharma to Present Clinical Data at the 2008 Annual
European Congress of Rheumatology |
| June 11 |
Biopure Phase III Orthopedic Trial Results Published in Journal of
Trauma |
| June 11 |
Biovest Reports Blinded Results for Phase 3 Study Evaluating
Anti-Cancer Vaccine, BiovaxID, which Shows 100% Difference in
Disease-Free Survival at 36 Months in the Comparative Arms |
| June 11 |
Biovest Reports Blinded Results for Phase 3 Study Evaluating
Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in
Disease-Free Survival at 36 Months in the Comparative Arms |
| June 11 |
Panacos Presents Bevirimat Patient Response Predictors at the
International HIV Drug Resistance Workshop |
| June 11 |
Pierre Fabre Medicament Announces Submission of a Market
Authorization Application for Milnacipran in Europe : New Data from
European Phase III Fibromyalgia Study presented at EULAR congress |
| June 11 |
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly
Improved Signs and Symptoms of Rheumatoid Arthritis |
| June 11 |
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in
Melanoma |
| June 11 |
New evidence shows MabThera is more effective than a second TNF
inhibitor in rheumatoid arthritis patients who have interrupted
anti-TNF therapy due to lack of efficacy |
| June 11 |
New potential application for SUBA-Itraconazole in oncology |
| June 11 |
Phase 3 Data Show Efficacy of Golimumab in Patients with Active
Rheumatoid Arthritis Previously Treated with Anti-TNF Agents |
| June 11 |
Ardea Biosciences Presents Inflammation Program Data for Arthritis
and Gout at 2008 Annual European Congress of Rheumatology |
| June 11 |
Diabetes Experts Respond to New Clinical Trials |
| June 11 |
Optimer to Present Additional Data from OPT-80 Phase 2A Study for
Clostridium difficile Infection at Anaerobe 2008 Congress |
| June 11 |
New Meta-Analysis Confirms Safety Profile for NeoRecormon in
Treating Anaemia in Cancer Patients |
| June 11 |
Novo Nordisk Discontinues Phase 3 Clinical Trial with Novoseven in
Trauma |
| June 11 |
Interim Results for the Zilver PTX Clinical Study from Cook Medical
Show Promise for Improving the Treatment of Blockages in the
Femoropopliteal Artery |
| June 11 |
Intermezzo 3.5 mg Achieves Greater Early Bioavailability Than
Ambien 10 mg Despite 65% Lower Dose |
| June 11 |
Angiotech's Corporate Partner, Cook Medical, Announces Positive
Interim Results for its Zilver PTX Clinical Study |
| June 11 |
MTR106 Tablets Were Found to be Effective in Acute Migraine Attacks |
| June 12 |
Human Genome Sciences Reports Positive Long-Term Data for
LymphoStat-B in Patients With Active Systemic Lupus Erythematosus |
| June 12 |
Incyte to Host EULAR Webcast and Conference Call on June 12 |
| June 12 |
Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in
Phase IIa Rheumatoid Arthritis Study |
| June 12 |
Promising Data Presented on GenVec Malaria Vaccine Program |
| June 12 |
Dermatologic Surgery Journal Publishes Comparison of Global
PMMA-Based Dermal Fillers Showing Superior Characteristics of
ArteFill Microspheres |
| June 12 |
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free
Survival as Predictor of Improved Overall Survival |
| June 12 |
Iomai Announces Publication in The Lancet of Phase II Study
Demonstrating Significant Efficacy of Travelers’ Diarrhea
Vaccine |
| June 12 |
The New England Journal of Medicine Publishes Study Investigating
the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu
Vaccine |
| June 12 |
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data
Presented at Annual European Congress of Rheumatology |
| June 12 |
Ambrilia Biopharma Presents New HIV Integrase Inhibitors |
| June 12 |
Iomai Announces Publication in The Lancet of Phase II Study
Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine |
| June 12 |
Geron Presents Data at ISSCR Showing That Its Embryonic Stem Cell
Therapeutic for Heart Failure Evades Direct Attack by the Human
Immune System |
| June 12 |
Pharmaxis Long-Term Safety Study of Bronchitol Completes |
| June 12 |
Positive Phase I/II Data of IDX899 Confirm Potent Antiviral
Activity and Favorable Safety Profile in Treatment-Naive
HIV-Infected Patients |
| June 12 |
BioSante Pharmaceuticals VP of Clinical Development To Present at
The Endocrine Society's 90th Annual Meeting |
| June 12 |
Tengion Scientists Publish Key Preclinical Findings Demonstrating
the Benefits of Organ Regeneration Vs. Repair |
| June 12 |
Orencia (abatacept) Provided an Increasing Degree of Inhibition of
Structural Damage Through Three Years in Adults with Moderate to
Severe Rheumatoid Arthritis |
| June 12 |
Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II
Retreatment Studies of Tovaxin for Multiple Sclerosis |
| June 12 |
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial
Results of APD125 for the Treatment of Insomnia at 22nd Annual
Meeting of the Associated Professional Sleep Societies |
| June 12 |
Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial
Results of APD125 for the Treatment of Insomnia at 22nd Annual
Meeting of the Associated Professional Sleep Societies |
| June 12 |
PTC Therapeutics Announces Data from Additional Clinical Studies of
PTC124 in Cystic Fibrosis Confirming Activity |
| June 12 |
Tumor Targeting Docetaxel Abstract Selected for Presentation at the
11th Liposome Research Days Conference |
| June 12 |
SILENOR Data Presented at the 22nd Annual Meeting of the Associated
Professional Sleep Societies |
| June 12 |
At Least 50% of Recent Onset Rheumatoid Arthritis Patients Become
Free of Signs and Symptoms Within 36 Weeks |
| June 12 |
New Self-Management Programme Offers Significant Benefits for
Arthritis Patients with Chronic Pain |
| June 12 |
Inspire's Phase 3 CF Trial, Using PARI's Nebulizer &
Compressor, Shows Positive Top-Line Results |
| June 12 |
Adalimumab Therapy Effective in Ankylosing Spondylitis, Rheumatoid
Arthritis and Psoriatic Arthritis Patients Refractory to Other
Anti-tnf Therapies |
| June 12 |
Hand Bone Mineral Density is an Effective Predictor of Mortality in
Rheumatoid Arthritis |
| June 12 |
Ovarian Function and Fertility Preserved in Women with Severe
Systemic Lupus Erythematosus Through Treatment with
Cyclophosphamide and Mycophenolate Mofetil |
| June 13 |
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for
Naproxcinod at EULAR |
| June 13 |
Acterma (tocilizumab) Significantly Reduces Rheumatoid Arthritis
Signs and Symptoms Regardless of Previous Therapy in Two New Global
Studies |
| June 13 |
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine
(VNP40101M) in Elderly Patients with High-Risk Myelodysplastic
Syndromes at the EHA Annual Meeting |
| June 13 |
New Long-Term Humira (adalimumab) Data Show Up to Seven-Year
Efficacy with Combination Treatment for Rheumatoid Arthritis |
| June 13 |
Humira (adalimumab) Data Show That Treating Early Rheumatoid
Arthritis With Combination Treatment Resulted in Cost Savings From
Improved Work Productivity |
| June 13 |
Data Show that Abbott's Humira (adalimumab) Reduced the Signs and
Symptoms of Ankylosing Spondylitis Up to Three Years |
| June 13 |
Array BioPharma Presents Additional Positive Phase 1 Results in Two
Programs at the 2008 Annual European Congress of Rheumatology |
| June 13 |
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for
Naproxcinod at EULAR |
| June 13 |
New data: Actemra the first and only biologic to show superiority
over current standard of care in RA |
| June 13 |
Higher Initial Dose of Glivec Achieved Better Early Responses Than
Standard Dose for Patients with Chronic Myeloid Leukemia |
| June 13 |
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of
Osteoarthritis of the Knee in New Study |
| June 13 |
Array BioPharma Presents Additional Positive Phase 1 Results in Two
Programs at the 2008 Annual European Congress of Rheumatology |
| June 13 |
Carbocisteine Can Reduce Worsening of COPD |
| June 13 |
Gilead Announces Interim 12-Month Phase III Study Results for
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis |
| June 13 |
Video: Higher Initial Dose of Gleevec Achieved Better Early
Responses than Standard Dose for Patients with Chronic Myeloid
Leukemia |
| June 13 |
VIVUS Announces Presentation of Qnexa Data at the 2008 BIO
International Convention |
| June 13 |
Transave Announces Positive Phase II Results for Once-Daily Arikace
in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas
Lung Infections |
| June 13 |
SIR-Spheres Microspheres Featured at the 2008 Society of Nuclear
Medicine Annual Meeting |
| June 13 |
Exelixis Presents Clinical Data Supporting the Safety and Initial
Clinical Activity of XL228 in Chronic and Acute Leukemia |
| June 13 |
SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression
in AML Xenograft Models |
| June 13 |
Study of Vidaza in Higher-Risk Patients with Myelodysplastic
Syndromes Reports Improved Overall Survival |
| June 13 |
Vidaza Continues to Show Significant Overall Survival Benefit When
Compared with Conventional Care Regimens Across the EU |
| June 13 |
Data from Phase II Exploratory Study Suggest That Orencia
(abatacept) May Delay Development of Rheumatoid Arthritis in Adults
with Undifferentiated Inflammatory Arthritis |
| June 13 |
Data Presented at the 13th Congress of the European Hematology
Association Demonstrate Advances in the Treatment of Patients with
High-Risk Myelodysplastic Syndromes |
| June 16 |
Vical Pandemic Influenza Vaccines Provide Complete Protection in
Animal Studies; The Journal of Infectious Diseases Publishes H5N1
Challenge Data |
| June 16 |
NanoViricides Anti-HIV Lead Drug Candidate Demonstrated Substantial
Improvement in Survival Time in Animal Model |
| June 16 |
Antisoma plc (UK) - Antisoma announces AS1413 (Xanafide)
presentation at EHA |
| June 16 |
Bionovo Discovers New Estrogen Regulatory Elements for Breast
Cancer and Osteoporosis Drugs |
| June 16 |
ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb
Schizophrenia Trial |
| June 16 |
ChemGenex’s Omacetaxine Demonstrates Activity in CML Patients
Who Have Failed Therapy with Multiple Tyrosine Kinase Inhibitors |
| June 16 |
Soliris Improved Fatigue Independent of Changes in Anemia in
Patients with PNH by Controlling Hemolysis |
| June 16 |
Romiplostim Data Show Potential Long-Term Efficacy and Safety in
Adults with Chronic ITP |
| June 16 |
Sunesis Pharmaceuticals Presents Data from Clinical Trials of
Voreloxin (formerly SNS-595) in Patients with Acute Myeloid
Leukemia at the 13th Congress of the European Hematology
Association |
| June 16 |
Adventrx Announces CoFactor Phase 2b Clinical Trial Overall
Survival Results |
| June 16 |
SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell
Proliferation |
| June 16 |
Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on
Neural Pathways Related to Temperature Regulation |
| June 16 |
Teva's Azilect 1 mg Tablets Meet End Points in ADAGIO Phase III
Trial |
| June 16 |
ChemGenex's Omacetaxine Demonstrates Activity in CML Patients Who
Have Failed Therapy With Multiple Tyrosine Kinase Inhibitors |
| June 16 |
Gentronix Use Abcellute Preserved Hepatocytes to Enhance in Vitro
Genotoxicity Testing |
| June 16 |
Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at
the International Society for Stem Cell Research Annual Meeting |
| June 16 |
Sensitivity Enhancements to Monogram's Trofile Assay Demonstrate
Improved Power to Select Patients for CCR5 Antagonist Therapy |
| June 16 |
Bionovo's Drug Candidate Shows In Vivo Safety and Efficacy in the
Treatment of Vaginal Atrophy |
| June 16 |
Nextrials and Allon Therapeutics Set New Benchmark for Releasing
Clinical Trial Results |
| June 16 |
Journal of Drugs in Dermatology Highlights Data Showing the
Benefits of Solubilized 5% Benzoyl Peroxide Gel in the Treatment of
Acne |
| June 16 |
Molecular Insight Pharmaceuticals, Inc. Reports Preclinical Data on
Solazed for Treatment of Metastatic Melanoma at Society of Nuclear
Medicine (SNM) Meeting |
| June 16 |
Novelos Therapeutics and MUSC Peer Reviewed Article Published in
Expert Opinion on Investigational Drugs |
| June 16 |
Quatrx Pharmaceuticals Presents Results From Ophena (Ospemifene
Tablets) Phase 3 Study Related to Treatment of Symptoms of
Vulvovaginal Atrophy |
| June 16 |
Neuromonics Announces Publication of Controlled Tinnitus Treatment
Study |
| June 16 |
US WorldMeds Completes Phase III Trial of Lofexidine for Treatment
of Opiate Withdrawal Symptoms |
| June 16 |
Data from Overseas Phase III Trial (RADIATE and AMBITION)
Demonstrates Efficacy of "Actemra," a Humanized Anti-Human IL-6
Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients |
| June 16 |
New Study Shows Benicar (olmesartan medoxomil) Reverses Blood
Vessel Damage Independent of Blood Pressure Lowering |
| June 16 |
Revlimid Data for Newly Diagnosed Multiple Myeloma Reported at a
Satellite Symposium During the 13th European Hematology Association
Congress |
| June 16 |
VaxInnate to Discuss Seasonal and Pandemic Flu Vaccines During BIO
2008 This Week |
| June 16 |
More Than Two-Thirds of Newly-Diagnosed Patients Who Are Prescribed
Medications for OCD Receive Inadequate Therapy |
| June 16 |
Pharming announces positive results from North American randomized
trial with rhucin |
| June 16 |
Tercica Announces Results from Increlex IGFD Patient Registry and
Other Increlex Studies at the 90th Meeting of the Endocrine Society |
| June 16 |
BaroFold Inc. Initiates First Human Studies for Multiple Sclerosis
Drug Candidate, BaroFeron |
| June 16 |
Preterax Prevents / Regresses Kidney Disease in Diabetics in
Addition to Life-saving Benefits |
| June 17 |
Akesis Pharmaceuticals Reports Positive Results from its Phase IIa
Trial of AKP-020 for Type 2 Diabetes |
| June 17 |
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015
and SBI-087 Data at the 2008 Annual European Congress of
Rheumatology Meeting |
| June 17 |
Elan and Wyeth Announce Encouraging Top-line Results from Phase 2
Clinical Trial of Bapineuzumab for Alzheimer's Disease |
| June 17 |
Clinical Data For Revlimid And Vidaza In Important Blood Cancers
Presented at The 13th European Hematology Association Congress |
| June 17 |
PLx Pharma Demonstrates Bioequivalence with Aspirin and PL 2100 --
Aspirin-PC |
| June 17 |
Lytix Reveals Further Details on First Cancer Candidate Oncopore at
BIO2008 |
| June 17 |
Elan and Wyeth Announce Encouraging Top-line Results from Phase 2
Clinical Trial of Bapineuzumab for Alzheimer's Disease |
| June 17 |
Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for
Endometriosis |
| June 17 |
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple
Sclerosis Patients and Presentation at BIO 2008 |
| June 17 |
Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study |
| June 17 |
invivodata Captures Primary Efficacy Data in Largest Controlled
Allergy Vaccine Trial |
| June 17 |
Osteologix to Present a Corporate Overview and Phase 2 Osteoporosis
Data at the BIO International Conference |
| June 17 |
TransMolecular Presents Imaging and Pharmacokinetic Analysis of
(131)Iodine-TM601 at Society for Nuclear Medicine Meeting |
| June 17 |
Lantheus Medical Imaging Presents Phase I Study Results of Novel
PET Myocardial Perfusion Imaging Tracer |
| June 17 |
Long-Term Safety Data on Lialda (mesalamine) for Patients With
Ulcerative Colitis Published in Leading GI Journal |
| June 17 |
Gloucester Pharmaceuticals Announces Phase 2 Data for Romidepsin
Showing Durable Response in Refractory CTCL |
| June 17 |
Effective Communication of Clinical Studies for Maximum Impact |
| June 17 |
Accentia Reports on Multiple Sclerosis Study: Revimmune Shows
Unprecedented Results in Reducing Disability and Improving
Functions |
| June 17 |
Novel Testosterone Gel Significantly Improves Insulin Sensitivity
and Sexual Function in Hypogonadal Men With Type 2 Diabetes and
Metabolic Syndrome |
| June 18 |
Panacos Announces Results of Bevirimat Prospective Study, which
Confirm Patient Response Predictors |
| June 18 |
New Subset Analysis of AndroGel Data Highlights Efficacy -
Regardless of BMI |
| June 18 |
Cytopia To Present Data on FMS Program With Anticancer Potential |
| June 18 |
EG011 (Refractory Angina) Demonstrates Ability to Grow New Blood
Vessels and Restore Heart Function Following Heart Attack |
| June 18 |
Two-Year Clinical Trial Findings Show Significant and Persistent
Reduction in Blood Pressure with CVRx Rheos Hypertension Therapy |
| June 18 |
Epigenomics Successfully Completes Larger Clinical Study in Early
Lung Cancer Detection |
| June 18 |
Avontec Announces Results of a Multiple Dose Clinical Phase I Study
with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment
in Male Healthy Volunteers |
| June 18 |
Theratechnologies Reports Positive 26-week Results for Its Second
Tesamorelin Phase 3 Trial |
| June 18 |
Micardis-Based Regimens Help More Patients Achieve Their Blood
Pressure Goals |
| June 18 |
Molecular Insight Pharmaceuticals, Inc. Presents Three Studies on
Trofex Program for Prostate Cancer Diagnosis and Staging |
| June 18 |
Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation
at the Endocrine Society Annual Meeting |
| June 18 |
Molecular Insight Pharmaceuticals, Inc. Reports Onalta Tissue
Distribution Data Support Clinical Development Program |
| June 18 |
Nventa Develops Proprietary Vaccine Adjuvant |
| June 18 |
Cortex and Top Alberta Government Officials Meet to Discuss
Progress on Ampakine Compounds at the 2008 Bio Conference |
| June 18 |
Biotie's VAP-1 Antibody Program to Proceed to Clinical Studies in
Rheumatoid Arthritis and Psoriasis Patients |
| June 18 |
Kidney Transplant Patients May Benefit from Going Off of Certain
Immunosuppressive Drugs |
| June 19 |
Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma
Into Long-Term Remission - Without Chemotherapy or Radiation |
| June 19 |
Metabasis Announces Promising Results from Its Phase 1b Clinical
Trial for MB07811, Its Novel Product Candidate for the Treatment of
Hyperlipidemia |
| June 19 |
Bavarian Nordic Reports Interim Data from Phase I/II Studies with
Breast Cancer Vaccine |
| June 19 |
Sepracor Announces Phase III Data for Eslicarbazepine Acetate
Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs |
| June 19 |
Forest Laboratories Announces Positive Results from Phase III
Clinical Studies of Ceftaroline for the Treatment of Complicated
Skin and Skin Structure Infections |
| June 19 |
CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and
Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab
(Erbitux). |
| June 19 |
Oncolin Therapeutics Announces Its Cancer Technology Will Be
Presented at the 20th EORTC-NCI-AACR Symposium |
| June 19 |
Sepracor Announces Phase III Data for Eslicarbazepine Acetate
Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs |
| June 19 |
Generex Biotechnology Corporation to Hold Conference Call on
Tuesday, June 24th to Update Investors on Phase III Trial of
Generex Oral-lyn and Other Corporate Activities |
| June 19 |
Speedel Reports on Data Published at Hypertension 2008 Medical
Congress |
| June 19 |
Published Study Reveals Next Pharmaceuticals' Flavoxine Reduces
Multiple Heart Health Risk Factors Including High Cholesterol |
| June 19 |
Weight Gain Within the Normal Range Increases Risk of Chronic
Kidney Disease |
| June 20 |
EPIX Pharmaceuticals to Present at the Eighth Annual
Structure-Based Drug Design Conference |
| June 20 |
Controlling Perioperative Hypertension with Cleviprex Reduces Risk
of Heart Attack and of Death Following Cardiac Surgery, According
to New Analyses |
| June 20 |
Active Biotech's Novel MS Compound Laquinimod Featured in the
Scientific Publication The Lancet |
| June 20 |
Pivotal Pulmonary Arterial Hypertension Study Published in the
Lancet Concludes That Bosentan (tracleer) Demonstrates Benefits in
Patients with Mildly Symptomatic WHO Functional Class II Disease |
| June 20 |
Generex Biotechnology Presented Data at The Endocrine Society's
Annual Meeting |
| June 20 |
Pivotal Pulmonary Arterial Hypertension Study Published in The
Lancet Concludes That Bosentan (Tracleer) Demonstrates Benefits in
Patients With Mildly Symptomatic WHO Functional Class II Disease |
| June 20 |
New Data Show Merck's Rotateq Helped Reduce Hospitalizations and
Emergency Room Visits Due to Rotavirus Gastroenteritis for up to
Three Years after Vaccination |
| June 20 |
Zebinix a New Anti-epileptic Drug That Offers Hope to Epilepsy
Sufferers Major Phase III Study Data Released |
| June 23 |
Webinar on June 25 to Focus on Opportunity for Treating Chronic
Pain, Migraine and Muscle Spasticity Through Inhibition of
Neurotransmitter Glutamate |
| June 23 |
Stroke Study Reveals a Key Target For Improving Treatment |
| June 23 |
Olanzapine Long-Acting Injection (LAI) Data Presented at First
Annual Schizophrenia International Research Society Conference |
| June 23 |
Tranzyme Pharma Announces Successful Thorough QT/QTc Study of
Ghrelin Agonist TZP-101 |
| June 23 |
Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at
the American Headache Society Annual Scientific Meeting |
| June 23 |
A Shot in the Arm Against Breast Cancer |
| June 23 |
PREPARED Study Demonstrates Requip-Modutab Is a Highly Effective
Treatment in the Management of Parkinson's Disease |
| June 23 |
Management of High Blood Pressure Immediately After Stroke |
| June 23 |
Study Shows That Small Protein Can Broaden Immune Response in
Humans |
| June 23 |
TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical
Data for Acute Migraine at 50th Annual Scientific Meeting of the
American Headache Society |
| June 23 |
Research and Markets: Determine the Impact of the ENHANCE Study on
Vytorin and Zetia Use |
| June 24 |
CV Therapeutics Announces Archives of Internal Medicine Publication
of Study Showing 20 Percent of Heart Attack Patients in Premier
Registry Experienced Angina at One Year |
| June 24 |
Akesis Pharmaceuticals and Charles River Laboratories to Begin
13-Week Animal Study for AKP- 020 |
| June 24 |
RhuDex Achieves Positive Results in Clinical Phase IIa Trial |
| June 24 |
MediGene Achieves Positive Results with RhuDex in Clinical Phase
IIa Trial |
| June 24 |
Genta Updates Progress of its Phase 3 Trial of Genasense in
Patients with Advanced Melanoma |
| June 24 |
Phase I Intravenous Trial for Melanoma, Prostate and Breast Cancer
– Cohort Complete |
| June 24 |
Independent Clinical Trial Investigators To Present New Data on
Nymox's NX-1207 Drug in Development For Benign Prostatic
Hyperplasia |
| June 24 |
Titan Pharmaceuticals Announces Spheramine Presentations at 12th
International Congress of Parkinson's Disease and Movement
Disorders |
| June 24 |
First Results for Phase IIa Data of UCB's Lacosamide for Treatment
of Fibromyalgia |
| June 25 |
Nerve Cells Derived from Embryonic Stem Cells and Transplanted into
Mice May Lead to Improved Brain Treatments |
| June 25 |
VGX Announces Publication of Preclinical Data for the Company's
Avian Flu Vaccine Candidate in PLoS ONE Journal |
| June 25 |
Ardea Biosciences Reports Additional Positive Phase 2a Results for
Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction
in Plasma Viral Load with Once-Daily Dosing |
| June 25 |
Quest PharmaTech Announces Interim Results from Phase I/II Clinical
Trial for Photodynamic Treatment for Hair Removal |
| June 25 |
The Lancet Publishes Results from the Landmark Phase III
Rivaroxaban Study RECORD2 |
| June 25 |
Immutep Reports that LAG-3 Enhances Activity of a Cellular Cancer
Immunotherapy in Preclinical Studies |
| June 25 |
TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on
the Opportunity for Treating Chronic Pain, Migraine and Muscle
Spasticity Through Inhibition of Neurotransmitter Glutamate |
| June 25 |
Journal of Antimicrobial Chemotherapy Paper Supports Additional
Role for Cethromycin as Potential Treatment for Infections Caused
by Community- Associated Methicillin Resistant Staphylococcus
Aureus (CA-MRSA) |
| June 25 |
First Comprehensive Report on Colorectal Cancer (CRC) Care in
Europe and Australia Reveals Urgent Need for Action |
| June 25 |
Clavis Pharma ASA Announces Promising Results for Oral CP-4126 |
| June 25 |
High Levels of Urinary Albumin in the Normal Range Predict
Hypertension |
| June 26 |
Results from ValiRx in the Epigenetics Field Announced Below |
| June 26 |
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162)
Significantly Improves Sleep in Patients with Chronic Insomnia |
| June 26 |
Alimera Reports Results From the Three-Month Interim Readout of the
Human PK Medidur FA Study |
| June 26 |
Radiesse Dermal Filler Featured Prominently in Journal of
Dermatologic Surgery Special Issue on Fillers |
| June 26 |
Promising In Vivo Data for VAL 101 Compound Targets Pancreatic
Cancer, based on GeneICE Gene Silencing Technology |
| June 26 |
VIVUS Announces New Data from Qnexa Diabetes Study |
| June 26 |
Cytheris Announces Publication of IL-7 Oncology Data in The Journal
of Experimental Medicine |
| June 26 |
NeuroSearch Successfully Completes Phase I with ACR325 And
Announces the Decision to Progress Development into Phase II
Proof-of-Concept Studies in Parkinson’s disease and Bipolar
Disorder |
| June 26 |
Avastin Shows Unprecedented Benefits in Colorectal Cancer Patients,
Irrespective of K-Ras Gene Mutation |
| June 26 |
Access Pharmaceuticals Presents New Data at International Symposium
Showing Company's Angiolix Monoclonal Antibody has Potential to
Treat Cancer by Attacking Cancer Stem Cells |
| June 26 |
Anavex Life Sciences Corp. will Present New Findings at the
International Conference on Alzheimer's Disease 2008 (July 26-31,
2008, Chicago, USA) |
| June 26 |
Zysolin Improves Survival in Pivotal Animal Studies |
| June 26 |
pSivida Announces Interim Results from the Three-Month Readout of
the Human PK Medidur FA Study |
| June 26 |
New England Journal of Medicine Publishes Results from Two of the
Landmark Phase III RECORD Studies with Rivaroxaban |
| June 26 |
iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B)
Preclinical Results |
| June 26 |
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO
MedPredict Report |
| June 27 |
New Data Show Preemptive Treatment May Significantly Reduce Skin
Toxicities in Patients Receiving Vectibix (Panitumumab) |
| June 27 |
New England Journal of Medicine and the Lancet Publish Results from
Landmark Rivaroxaban Studies |
| June 27 |
Optimer Reports Additional Data on Investigational Compound OPT-80
at Anaerobe 2008 Congress |
| June 27 |
Merck's Investigational Migraine Treatment Telcagepant Improved
Pain and Migraine-Associated Symptoms in Phase III Study |
| June 27 |
Data Show Significantly More Patients Were Pain-Free with Treximet
(sumatriptan and naproxen sodium) Tablets in the Acute Treatment of
Probable Migraine Without Aura in Adults |
| June 27 |
Treximet (sumatriptan and naproxen sodium) Tablets Shown to be
Effective in Patients Who Previously Had Poor Response to, or Did
Not Tolerate, Migraine Treatment with a Short-Acting Triptan |
| June 27 |
Liver Phase I Results Presented at WCIO 2008 & Best of ASCO |
| June 27 |
Combination Therapy: A Real Advance for Cancer Patients with
Follicular Lymphoma |
| June 27 |
International Team Locates Key Player in Muscle Regeneration |
| June 30 |
Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan
in Alzheimer's Disease |
| June 30 |
MAP Pharmaceuticals Reports Positive Pharmacological Response Data
for Migraine Product Candidate at the American Headache Society
Annual Meeting |
| June 30 |
Zogenix Announces Clinical Study Results for Sumatriptan DosePro, a
Novel Migraine Treatment |
| June 30 |
Teva & ANP Announce That ATL/TV1102, a Novel Drug for the
Treatment of Relapsing Remitting Multiple Sclerosis (RRMS),
Demonstrated Significant Reduction in Disease Activity |
| June 30 |
Oncolin Therapeutics Announces the Discovery of a New More
Effective Anti-Cancer Treatment in Experimental Brain Tumor Models |
| June 30 |
Sangamo BioSciences Announces Nature Biotechnology Study
Demonstrating the Use of Zinc Finger Nucleases to Generate HIV
Resistant T Cells |
| June 30 |
Early Results from Ongoing Clinical Study of Hepatitis C Vaccine
Delivered by Inovio Biomedical's Electroporation System Show
Increased T-Cell Responses and Reduced Viral Loads |
| June 30 |
ThromboGenics Announces Positive Results from its Phase IIb Trial
of Microplasmin in Vitrectomy (MIVI III) |
| June 30 |
Aradigm Reports Successful Top-line Phase 2 Data with Inhaled
Liposomal Ciprofloxacin for Cystic Fibrosis |
| June 30 |
Erbitux – Enhanced Efficacy Demonstrated in Patients With
KRAS Wild-Type Tumors in 1st-Line Metastatic Colorectal Cancer |
| June 30 |
The GI Company Reports Additional Phase II Clinical Data for Oral
Mucositis |
| June 30 |
DG041 Blocks Platelet Aggregation Through a Novel Mechanism and
does not Increase Bleeding Time When Given Alone or with Plavix or
Aspirin |
| June 30 |
Data Presented at American Headache Society's Annual Scientific
Meeting Show Primary Endpoint Met as Well as Improvement on
Important Secondary Endpoints in Phase IIb Acute Migraine Trial of
TorreyPines Therapeutics' Tezampanel |
| June 30 |
Results of Flurizan in Clinical Phase III Trial |
| June 30 |
Hope for Progeria - Successfully Validated on Mice, a Treatment
Could Soon be Tested on Children |
| June 30 |
Rivaroxaban is First Novel Oral Anticoagulant to Significantly
Reduce the Composite Outcome of Symptomatic VTE and Death |
| June 30 |
Isis Pharmaceuticals Conference Call Notice |
| June 30 |
Phase II Results for Low-Dose Oral Immune Tolerance Therapy
(ARG201) in Systemic Scleroderma Published |
| June 30 |
NuPathe Reports Positive Phase I Results for NP101, a Novel
Transdermal Patch for Acute Migraine |
